Table 3 Predictors of poor treatment outcome (i.e. death or failure), loss to follow-up, and unfavourable outcomes (i.e. death, treatment failure, or loss to follow-up) in patients with multidrug-resistant and extensively drug-resistant tuberculosis in Hunan Province, China, 2011–2014
Variables | Poor treatment outcome | Lost to follow up | Unfavourable outcome | |||
|---|---|---|---|---|---|---|
CHRb (95% CI) | AHRc (95% CI) | CHRb (95% CI) | AHRc (95% CI) | CHRb (95% CI) | AHRc (95% CI) | |
Age in years | 1.0 (0.9–1.0) | 1.0 (0.9–1.01) | 1.01(1.0–1.03) | 1.0 (0.9–1.02) | 1.01 (1.0–1.02) | 1.01 (1.0–1.02 |
Male gender | 1.2 (0.7–2.0) | 1.1 (0.7–1.8) | 1.4 (0.9–2.2) | 1.4 (0.9–2.1) | 1.4 (1.04–2.0) | 1.3 (0.97–1.9) |
Occupationa | ||||||
 Labourer | 0.5 (0.1–3.1) | 0.3 (0.06–2.1) | 1.6 (0 .7–3.8) | 1.9 (0.8–4.3) | 1.2 (0.6–2.7) | 1.3 (0.6–2.8) |
 Employed | 0.4 (0.1–3.0) | 0.4 (0.05–3.2) | 0.6 (0.2–2.0) | 0.7 (0.2–2.4) | 0.5 (0.2–1.4) | 0.6 (0.2–1.5) |
 Unemployed | 2.0 (0.7–4.9) | 1.8 (0.7–4.8) | 1.1 (0.5–2.) | 1.4 (0.6–3.2) | 1.5 (0.8–2.7) | 1.7 (0.9–3.2) |
 Other/unknown | 1.5 (0.8–2.8) | 1.4 (0.7–2.6) | 0.9 (0.5–1.6) | 1.01 (0.5–1.8) | 1.0 (0 .7–1.6) | 1.1 (0.7–1.8) |
Treatment starting yeara | ||||||
 2011–2012 | 2.8 (1.5–5.2) | 2.8 (1.4–5.0) | 0 .6 (0.4–1.1) | 0.6 (0.3–1.03) | 1.1 (0 .7–1.5) | 1.0 (0.7–1.5) |
 2013 | 2.1 (1.2–3.8) | 2.0 (1.1–3.8) | 0 .7 (0 .5–1.1) | 0.7 (0.5–1.1) | 1.0 (0.7–1.4) | 0.9 (0.7–1.4) |
Previous anti-TB treatment | 1.8 (0.8–4.2) | 1.8 (0.8–4.2) | 0 .7 (0.5–1.2) | 0.8 (0.5–1.2) | 0.9 (0.6–1.4) | 0.9 (0.6–1.4) |
Resistant to Ethambutol | 1.2 (0.8–2.0) | 1.3 (0.8–2.1) | 1.1 (0.7–1.5) | 1.1 (0.7–1.6) | 1.1 (0.8–1.5) | 1.2 (0.9–1.6) |
Resistant to second-line injectable drug | 1.3 (0.8–2.2) | 1.3 (0.8–2.1) | 0.7 (0 .4–1.0) | 0.7 (0.5–1.02) | 0 .8 (0.6–1.1) | 1.7 (0.5–5.4) |
Resistant to Ofloxacin | 2.8 (1.4–5.6) | 3.1 (1.5–6.3) | 0.9 (0.4–1.8) | 1.01 (0.5–2.1) | 1.5 (0.9–2.5) | 1.7 (1.07–2.9) |